HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Salonpas Spreads Into OTC Diclofenac Arthritis Gel

Executive Summary

Hisamitsu America launches Salonpas Arthritis Pain Relief Gel with same active ingredient, diclofenac sodium 1% gel, that became available OTC for the first time in the US in 2020 with GSK’s Voltaren Arthritis Pain formulation.

You may also be interested in...



OTC Topicals: Salonpas Has Online Portal For Doctors, HurriCaine Offers Single-Dose Oral Swabs

Hisamitsu America launches online portal exclusively for health care professionals. Also in OTC topical space, Beutlich Pharmaceuticals extends HurriCaine benzocaine gel and spray line with oral anesthetic single-dose packages in five flavors.

In GSK Challenge Of Salonpas Claims, NAD Embarks On Review Of Unchartered Argument

Hisamitsu America’s severity of pain claims for Salonpas challenged by GSK are more nuanced than what label indications support, but touting its regulatory approval doesn’t convey a message that other products aren’t subject to as rigorous pre-market evaluations.

OTC Decisions August-October: More Providers Enter Diclofenac, Lansoprazole, Loratadine Markets

CDER’s August-September OTC application approvals are highlighted by Arbor Pharmaceuticals’ ivermectin 0.5% lice treatment. Orange Book changes also include four firms’ approvals for labeling to market generic equivalents of Voltaren Arthritis Relief launched as an OTC switch since earlier in 2020.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS151117

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel